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Abstract 
Background: Advanced glycation end products (AGEs) play a role in the development of late complications and ath‑
erosclerosis in diabetes by engaging the receptor for advanced glycation end products, RAGE. Receptor binding leads 
to activation of the vascular endothelium and increased inflammation in the vessel wall. The soluble variants of the 
receptor, endogenous secretory RAGE (esRAGE) and the cleaved cell‑surface part of RAGE, which together comprise 
soluble RAGE (sRAGE), are suggested to have a protective effect acting as decoys for RAGE. We aimed to test whether 
high levels of soluble variants of RAGE could be protective against atherosclerosis development.
Methods: Participants in the prospective atherosclerosis and childhood diabetes study were examined at baseline 
(aged 8–18) and at follow‑up after 5 years. Both sRAGE and esRAGE were measured by immunoassay in 299 patients 
with type 1 diabetes and 112 healthy controls at baseline and 241 patients and 128 controls at follow‑up. The AGEs 
methylglyoxal‑derived hydroimidazolone‑1 (MG‑H1) and carboxymethyllysine (CML) were measured by immunoas‑
say. The surrogate markers of atherosclerosis assessed were carotid intima‑media thickness (cIMT), C‑reactive protein 
(CRP) and Young’s modulus, measures of arterial wall thickness, inflammation and arterial stiffness, respectively.
Results: Levels of sRAGE and esRAGE correlated strongly both at baseline and at follow‑up in both diabetes patients 
and controls. With increasing age, mean values of both variants declined, independent of gender, diabetes or pubertal 
stage. In the diabetes group, multiple regression analysis showed a positive association between both variants of solu‑
ble RAGE and cIMT. There was no significant relationship with Young’s modulus, but a negative association between 
sRAGE at baseline and CRP at follow‑up. The ratios between the AGEs and the variants of soluble RAGE were increased 
in diabetes patients compared to controls.
Conclusions: The results show a possible protective effect of high levels of sRAGE at baseline against inflammation 
5 years later, but not on arterial stiffness or wall thickness, in this cohort of adolescents and young adults with T1D.
Keywords: Advanced glycation end products, Receptor for advanced glycation end products, sRAGE, esRAGE, 
Atherosclerosis, Type 1 diabetes, CRP
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Background
Advanced glycation end products (AGEs) have been 
implicated in the pathogenesis of both microvascular 
complications and accelerated atherosclerosis in type 
1 diabetes (T1D) [1, 2]. A proposed mechanism for the 
deleterious effect of AGEs is engagement of the receptor 
for AGEs, RAGE, which is a multiligand transmembrane 
receptor in the immunoglobulin superfamily present on 
the surface of various cell types in atherosclerotic lesions 
[3–5]. Two of the AGEs that potentially bind to RAGE 
are carboxymethyllysine (CML) and methylglyoxal-
derived hydroimidazolone-1 (MG-H1) [6, 7]. Receptor 
binding leads to activation of monocytes and the vascu-
lar endothelium and increases inflammation in the vessel 
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wall [8, 9]. A mouse cell model indicates that RAGE also 
mediates AGE-induced macrophage migration [10].
RAGE has two soluble forms prevalent in human 
plasma. One created as the membrane bound receptor 
is cleaved by metalloproteinases [11], and the other pro-
duced by alternative splicing of the RAGE gene [12]. The 
latter is known as endogenous secretory RAGE (esRAGE) 
[13], and together they constitute plasma soluble RAGE 
(sRAGE). Estimates indicate that esRAGE accounts for 
20–50 % of sRAGE [14, 15].
It has been postulated that both soluble variants of 
RAGE work as decoys for AGEs, reducing RAGE signal-
ing and inflammation [16]. In a mouse model, treatment 
with intraperitoneal sRAGE suppressed the accelerated 
atherosclerosis of diabetes [17]. This suggests that high 
levels of sRAGE protect against the atherogenic effect of 
AGEs. Studies in T1D have, however, shown conflicting 
results. Levels of soluble variants of RAGE both lower 
[18–20] and higher [21–23] than controls have been 
demonstrated. Previously, Katakami et al. have found an 
inverse association between levels of esRAGE and carotid 
intima media thickness (cIMT) both cross-sectionally 
[18] and longitudinally in young adults [24]. Nin et  al., 
however, showed a positive association between sRAGE 
and cardiovascular events and all-cause mortality [22, 
25]. The seemingly contradictory results might be due to 
the different ethnic origin of the study populations [26], 
but more likely reflect the complexity of the regulation of 
the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes. 
This implies that AGEs or sRAGE alone may not be par-
ticularly informative as biomarkers, and an AGE/sRAGE 
ratio has been proposed as an improvement [27].
In this study, we aimed to investigate longitudinally 
whether higher levels of soluble variants of RAGE protect 
against atherosclerosis development in young patients 
with T1D compared to healthy controls.
Methods
Study population
The atherosclerosis and childhood diabetes (ACD) pro-
spective study was initiated in 2006, comprising 314 
diabetes patients and 120 controls, all between 8 and 
18 years old, from the South East health region of Nor-
way. The non-diabetic controls were mainly classmates of 
the diabetes patients. The details of the cohort and inclu-
sion process have previously been described [28]. From 
2011 to 2013, the participants were encouraged to attend 
a 5-year follow-up, and 80  % agreed. An additional 38 
control subjects were also enrolled at this time.
Both at baseline and at follow-up, blood samples were 
taken in the morning between 0800 and 1000 a.m. after 
an overnight fast. This was followed by carotid ultra-
sound and a clinical examination.
All parents and participants over 18  years old have 
given their written informed consent. The protocol, both 
at baseline and follow-up has been approved by the Nor-
wegian Regional Committee for Research Ethics, and the 
study has been conducted according to the Declaration of 
Helsinki.
Laboratory methods
All blood samples were centrifuged at 2500×g for 10 min 
immediately after venipuncture and stored at −80  °C 
until analysis. Serum sRAGE and esRAGE were meas-
ured using enzyme-linked immunosorbent assay (ELISA) 
kits (Quantikine, R&D Systems, Minneapolis, MN, USA 
and B-Bridge International Inc., Cupertino, CA, USA 
respectively) according to the manufacturer’s instruc-
tions. The inter-assay coefficients of variation (CV) in our 
laboratory were 5.8 % for sRAGE and 5.7 % for esRAGE. 
At baseline 411 participants (299 diabetes patients, 112 
controls) had valid measurements. At follow-up 369 
(241 diabetes patients and 128 controls) were tested. 318 
participants (231 diabetes patients and 87 controls) had 
measurements at both baseline and follow-up. All sam-
ples from both timepoints were measured in the same 
run to avoid bias due to assay variability.
MG-H1 and CML were measured by dissociation-
enhanced lanthanide fluorescent immunoassay (DELFIA) 
as previously described in detail [29–31].
Images of the common carotid arteries (CCAs) at base-
line were obtained using a Siemens Acuson Sequoia 512 
(Siemens Acuson; Mountain View, CA, USA) ultrasound 
scanner equipped with a linear array 14 MHz transducer. 
Further details have been described previously [28]. At 
follow-up, the images of the CCAs were obtained using a 
Zonare Z-one ULTRA (Zonare Medical Systems; Moun-
tain View, CA, USA) ultrasound scanner equipped with a 
linear array 8 MHz transducer. The cIMT measurements 
were performed using M’Ath 3.2.0 (Intelligence in Medi-
cal Imaging; Paris, France). All cIMT measurements were 
from the far wall in end-diastole. Blood pressure for cal-
culating Young’s modulus was assessed using a standard 
oscillometric device over the brachial artery.
CRP was determined by high sensitivity ELISA (DRG 
Instruments GmbH, Germany) with a detection limit of 
0.1 mg/L. The inter-assay CV was <5 %.
HbA1c was measured at a DCCT-standardized labo-
ratory using high performance liquid chromatography 
(Variant; Bio-Rad, Richmond, CA, USA), CV <3 %. Other 
routine laboratory analyses were performed by conven-
tional methods.
Statistical analysis
Demographic and clinical data are presented as either 
proportions, means with their standard deviations (SD) 
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or medians with the 25th and 75th percentile. Differences 
in continuous variables between groups were tested with 
the Student t test, alternatively the Mann–Whitney U-test 
for non-normally distributed data. Correlation analyses 
between continous variables were performed using Pear-
son’s correlation coefficient (r) for normally distributed 
data, or otherwise Spearman’s rho (ρ). Univariate linear 
regression analysis was performed to identify associations 
between sRAGE and esRAGE as exposure variables and 
surrogate markers of atherosclerosis as outcome variables. 
Only variables with significant relationships with both the 
exposure and the outcome variables were considered as 
possible confounders and included in a multivariate anal-
ysis. Adjustment for multiple confounding factors was 
performed using multivariate linear regression analysis 
with a manual backward elimination procedure. CRP was 
loge-transformed to achieve normally distributed residu-
als. A significance level of 5 % was used.
In addition, multivariate linear regression analysis 
with a manual backward elimination procedure was 
performed to identify predictors for soluble variants of 
RAGE at follow-up. Any variable with a p value <0.20 
from the univariate analysis was considered a candidate 
for the multivariate model. All statistical analyses were 
performed using the SPSS software package for Mac, ver-
sion 19.0 (SPSS, Chicago, IL, USA).
Results
Most of the diabetes patients (97  %) were on intensive 
insulin treatment using insulin pumps or >4 insulin injec-
tions a day. At baseline, comparison with the Norwegian 
Childhood Diabetes Registry showed that our cohort was 
a representative sample of the young T1D population in 
Norway regarding gender, stage of puberty, HbA1c, blood 
pressure and lipid status [28]. Due to exclusion of par-
ticipants under 8 years of age, the patients in our cohort 
were slightly older, had longer diabetes duration, higher 
body mass index (BMI) and were more frequently pump 
users than the rest of the Norwegian children and adoles-
cents with diabetes. The clinical and metabolic character-
istics of the patients at baseline and follow-up are shown 
in Table 1. The diabetic patients had higher body weight, 
blood pressure and increased serum lipid levels compared 
to the control subjects both at baseline and at follow-up.
The results from the sRAGE and esRAGE assays and 
the measurements of surrogate markers of atherosclero-
sis are presented in Table  2. We found no difference in 
soluble variants of RAGE between the groups, except for 
lower levels of esRAGE in the diabetes group at baseline. 
As for cIMT and Young’s modulus, we found no signifi-
cant differences between the groups. CRP was signifi-
cantly elevated in the diabetes group both at baseline [32] 
and at follow-up.
Table 1 Clinical and metabolic characteristics
Mean values (SD)
a Median (25th and 75th percentile)
Baseline 5 year follow-up
Diabetes (n = 299) Controls (n = 112) p value Diabetes (n = 241) Controls (n = 128) p value
Diabetes duration (years)a 5.1 (2.9, 7.7) 9.6 (7.5, 12.6)
Insulin pump users (%) 53.3 61.3
Age (years) 13.7 (2.8) 13.4 (2.5) 0.207 18.7 (2.8) 18.7 (2.9) 0.895
Girls, n (%) 150 (50.2) 64 (57.1) 0.224 129 (53.5) 72 (56.3) 0.661
Height (cm) 160.5 (14.4) 157.6 (13.3) 0.060 171.2 (9.1) 172.1 (9.2) 0.383
Weight (kg) 54.8 (16.7) 48.5 (13.2) <0.001 71.0 (14.6) 66.9 (12.5) 0.006
BMI (kg/m2) 20.8 (3.9) 19.2 (3.1) <0.001 24.1 (4.3) 22.5 (3.4) <0.001
Waist circumference (cm) 71.1 (10.0) 66.8 (6.6) <0.001 79.0 (9.6) 75.5 (8.2) <0.001
Systolic blood pressure (mmHg) 101 (10.1) 98 (10) 0.025 112 (11) 111 (10) 0.656
Diastolic blood pressure (mmHg) 60 (8) 58 (7) 0.017 70 (8) 68 (8) 0.024
HbA1c (%) [mmol/mol, SD] 8.4 (1.2) [68, 13.1] 5.3 (0.3) [34, 3.3] <0.001 9.0 (1.4) [75, 15.3] 5.2 (0.3) [33, 3.3] <0.001
Total cholesterol (mmol/L) 4.6 (0.8) 4.3 (0.7) 0.001 4.8 (1.0) 4.4 (1.0) 0.001
HDL (mmol/L) 1.8 (0.4) 1.7 (0.4) 0.048 1.6 (0.5) 1.6 (0.4) 0.161
LDL (mmol/L) 2.5 (0.7) 2.3 (0.7) 0.016 2.7 (0.8) 2.5 (0.8) 0.014
Triglycerides (mmol/L)a 0.7 (0.5, 0.9) 0.7 (0.5, 0.9) 0.367 0.9 (0.6, 1.3) 0.8 (0.6, 1.0) 0.024
Apolipoprotein B (g/L) 0.74 (0.19) 0.66 (0.17) <0.001 0.90 (0.26) 0.79 (0.23) <0.001
Apolipoprotein A1 (g/L) 1.55 (0.28) 1.44 (0.33) 0.001 1.56 (0.31) 1.48 (0.27) 0.006
ApoB/ApoA1 0.5 (0.2) 0.5 (0.3) 0.698 0.6 (0.2) 0.5 (0.2) 0.025
Urine albumin/creatinine (mg/mmol)a 0.70 (0.40, 1.30) 0.63 (0.36, 1.33) 0.688 0.65 (0.30, 1.55) 0.34 (0.19, 0.90) 0.001
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The levels of sRAGE and esRAGE correlated strongly, 
both in the diabetes and the control group (Table  3). 
In the diabetes group, the boys had significantly higher 
sRAGE both at baseline [1752 (SD  =  609) vs. 1576 
(SD  =  584) pg/ml, p  =  0.011] and at follow-up [1682 
(SD = 609) vs. 1487 (SD = 557) pg/ml, p = 0.010] as well 
as higher esRAGE at baseline [0.39 (SD = 0.17) vs. 0.34 
(SD = 0.15) ng/ml, p = 0.005] than the girls. These dif-
ferences disappeared when excluding the girls using oral 
contraceptives from the analysis.
At baseline, there was a weak negative correlation 
between HbA1c and sRAGE (r = −0.148, p = 0.011) and 
esRAGE (r = −0.137, p = 0.018). There were no signifi-
cant correlations with HbA1c at follow-up or in the con-
trol group at any time point.
Natural progression of sRAGE and esRAGE
There was a decline in sRAGE and esRAGE levels with 
increasing age. Figure 1 shows levels of sRAGE in diabe-
tes patients and controls. For illustrative purposes, val-
ues from each patient at both baseline and follow-up are 
included. The graphs for esRAGE as well as for both solu-
ble variants of RAGE when separated by gender showed 
similar patterns. There was no decline in the levels of 
either soluble variant of RAGE across the five Tanner 
stages of puberty.
To determine whether this relationship with age was 
confounded by other factors, we performed regres-
sion analyses. At baseline, the association between age 
and esRAGE remained significant after controlling for 
the confounding effect of CRP in the diabetes group 
(B = −0.009, R2 = 0.082 and p = 0.009) and in girls with 
diabetes (B = −0.012, R2 = 0.123 and p = 0.008). Also, 
sRAGE was significantly associated with age in the con-
trol group (B = −47.1, R2 =  0.081 and p =  0.033, con-
trolling for MG-H1), in girls with diabetes (B = −61.6, 
R2 =  0.154 and p =  0.001, controlling for CRP) and in 
control girls (B = −99.1, R2 =  0.154 and p =  0.001, no 
confounding variables). At follow-up, esRAGE was not 
associated with age in any group. There was, however, 
significant associations between sRAGE and age in the 
diabetes group (B  =  −51.5, R2  =  0.131 and p  <  0.001, 
controlling for CRP), in boys with diabetes (B = −57.8, 
R2  =  0.071 and p  =  0.004, no confounding variables) 
and in girls with diabetes (B  =  −45.5, R2  =  0.152 and 
p =  0.016, controlling for CRP). When identifying pre-
dictors of esRAGE or sRAGE in the different groups, age 
was only significant for sRAGE at follow-up in the diabe-
tes group.
Soluble variants of RAGE and atherosclerosis
In multiple regression analyses we found significant asso-
ciations between soluble variants of RAGE and the sur-
rogate markers of atherosclerosis cIMT and CRP in the 
diabetes group. These are presented in Table  4. There 
were no significant associations in the control group, and 
there were no significant associations involving Young’s 
modulus in either group.
We also analyzed delta values (follow-up minus base-
line). We found no significant associations between 
Table 2 Soluble RAGE and surrogate markers of atherosclerosis
Mean values (SD)
a Median (25th and 75th percentile)
Baseline 5 year follow-up
Diabetes Controls p value Diabetes Controls p value
sRAGE (pg/ml) 1664 (602) 1773 (574) 0.100 1578 (589) 1585 (561) 0.909
esRAGE (ng/ml) 0.36 (0.16) 0.42 (0.16) <0.001 0.33 (0.21) 0.33 (0.13) 0.810
cIMT (mm) 0.45 (0.05) 0.44 (0.04) 0.067 0.51 (0.05) 0.51 (0.06) 0.324
Young’s modulus (kPa) 13.7 (2.8) 13.4 (2.5) 0.207 18.7 (2.8) 18.7 (2.9) 0.895
CRP (mg/l)a 0.50 (0.27, 1.84) 0.31 (0.19, 0.67) <0.001 1.16 (0.43, 3.64) 0.69 (0.28, 2.00) 0.002
Table 3 Coefficients of correlation (Pearson), all with p < 0.001
Diabetes group Control group
esRAGE baseline esRAGE follow-up sRAGE baseline esRAGE baseline esRAGE follow-up sRAGE baseline
esRAGE follow‑up 0.396 1 0.636 1
sRAGE baseline 0.800 0.295 1 0.775 0.597 1
sRAGE follow‑up 0.593 0.510 0.638 0.458 0.828 0.620
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baseline variants of soluble RAGE and delta CRP in 
either patient group. Due to different measurement 
techniques applied at each time point, we were unable 
to evaluate delta values for cIMT and Young’s modulus. 
Delta sRAGE and delta esRAGE were not correlated with 
either delta HbA1c, delta LDL or delta BMI.
AGE/soluble variants of RAGE ratios
At baseline, levels of MG-H1 were significantly increased 
in the diabetes group compared to controls, 154.4 
(SD = 40.8) vs. 142.8 (SD = 35.5) U/ml, p = 0.008. There 
was no significant difference in CML, 18.0 (SD = 4.4) vs. 
17.3 (SD = 5.7) U/ml, p = 0.152. All possible AGE/solu-
ble variants of RAGE ratios at baseline were significantly 
increased in the diabetes patients compared to controls 
(Table 5). In multivariate analyses, there were no signifi-
cant associations between AGE/soluble variants of RAGE 
ratios at baseline and surrogate markers of atherosclero-
sis 5 years later.
Discussion
The main findings in this study are the relationships 
between the soluble variants of RAGE and surrogate 
markers of atherosclerosis. Our analyses do not indicate 
a protective effect of high levels of sRAGE or esRAGE 
against atherosclerosis development measured by cIMT. 
In fact, in the diabetes group we found the opposite, that 
high levels of both sRAGE and esRAGE at baseline are 
significantly associated with higher cIMT 5  years later. 
This is in line with the studies by Nin et al. [22, 25]. On 
the other hand, baseline sRAGE was significantly nega-
tively associated with CRP, indicating a protective effect 
against inflammation. We found no significant associa-
tions between soluble variants of RAGE and any measure 
of atherosclerosis in the control group.
We have demonstrated a reduction in values of both 
sRAGE and esRAGE in the teens and early twenties, 
regardless of diabetes, gender, or pubertal stage. The asso-
ciation with age remained significant in several groups 
when controlling for confounding factors, particularly in 
girls. A similar reduction with increasing age has been 
shown in women below the age of 35 compared to older 
subjects [33]. Komosinska-Vassev et  al. have also shown 
decreasing esRAGE values with increasing age in subjects 
without significant disease, particularly in women [34]. 
The participants in our study were young and healthy, 
apart from T1D. The fact that we did not find an asso-
ciation between T1D and the reduction in sRAGE or 
esRAGE values suggests that this is a normal physiologic 
development. Most studies, however, show a signifi-
cant relationship between soluble variants of RAGE and 
disease states [35]. High levels of sRAGE are associated 
with healthy aging [36], but whether sRAGE is protective 
against disease, reduced in disease, or both, is unknown.
Fig. 1 Mean sRAGE and age. Values in diabetes patients (grey line) 
and controls (dotted line). The figure includes two values from each 
participant, one at baseline and one at follow‑up
Table 4 Significant associations in the diabetes group
Independent variable Dependent variable Beta value SE p value R2 Confounding variables
Baseline esRAGE Follow‑up cIMT 0.074 0.023 0.001 0.141 Gender, waist circumference, BMI
Baseline sRAGE Follow‑up cIMT 1.4 × 10−5 6.2 × 10−6 0.027 0.116 Gender, waist circumference, ApoB
Baseline sRAGE Follow‑up CRP −3.3 × 10−4 1.4 × 10−4 0.017 0.269 Height, medication, BMI
Table 5 AGE/soluble RAGE ratios
Median (25th, 75th percentile)
Ratio Diabetes patients Controls p value
MG‑H1/sRAGE 0.099 (0.071, 0.124) 0.083 (0.058, 0.117) 0.006
MG‑H1/esRAGE 461 (335,624) 332 (248,480) <0.001
CML/sRAGE 0.012 (0.008, 0.015) 0.010 (0.007, 0.013) 0.005
CML/esRAGE 53.4 (39.8, 72.4) 38.1 (28.6, 58.6) <0.001
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The strong correlation between baseline and follow-up 
values of both sRAGE and esRAGE indicate that changes 
in levels of soluble variants of RAGE over time in each 
patient are generally small. We also found strong correla-
tions between sRAGE and esRAGE both at baseline and 
follow-up. This suggests that esRAGE constitutes a large 
proportion of the measured sRAGE and consequently 
that the cleaved form of RAGE is less prevalent. This is 
in contrast to most other studies, where esRAGE is esti-
mated to constitute only 20 % of sRAGE [11, 14, 37, 38]. 
A possible explanation is that our subjects are younger 
and healthier than in the previous studies. This is sup-
ported by the only study that has assessed the levels of 
sRAGE and esRAGE using comparable immunoassays 
[15]. Higher levels of esRAGE compared to sRAGE in 
youth is reasonable since RAGE amplifies inflammation 
[9]. Older patients with more pronounced atherosclero-
sis or other inflammatory diseases would express more 
RAGE on the cell surface and subsequently release more 
cleaved RAGE into the circulation [39].
The regulation of the AGE-RAGE-sRAGE and AGE-
RAGE-esRAGE axes is only partly understood. RAGE 
is subject to regulated intramembrane proteolysis by 
ADAM10 (a disintegrin and metalloproteinase 10), 
shedding the cleaved variant of sRAGE in a process 
dependent on intracellular calcium levels [40]. Shed-
ding can also be induced by activation of G protein-
coupled receptors [41]. As for esRAGE, engagement of 
RAGE by methylglyoxal-modified human serum albu-
min stimulated production of RAGE and esRAGE to a 
similar extent in human umbilical vein endothelial cells. 
Interestingly, engagement of RAGE by carboxymethyl-
lysine-modified human serum albumin more selectively 
stimulated production of RAGE [42]. Ohe et  al. have 
shown that elements in exon 9B of the RAGE gene can 
modulate the ratio of RAGE/esRAGE production [43]. 
Levels of sRAGE are associated with albuminuria, indi-
cating that kidney function is important for esRAGE 
excretion [38]. Still, much is yet left to discover about 
the production and excretion of the soluble variants of 
RAGE. Even though sRAGE in our study was negatively 
associated with CRP 5  years later, this does not neces-
sarily imply a causal relationship. The finding indicates a 
protective effect, but as inflammation most likely alters 
the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes 
in a still unpredictable fashion, sound conclusions are 
difficult to reach.
The AGE/sRAGE ratio has been proposed as an 
improved biomarker for the AGE-RAGE-sRAGE axis 
[27]. A higher ratio is associated with pre-eclampsia in 
women with T1D [44], and we also found higher ratios 
in diabetes patients compared to controls in this study. 
However, we found no significant associations with 
surrogate markers of atherosclerosis, rendering the ratios 
less useful than sRAGE alone. Furthermore, the ratios are 
hardly easier to interpret than the separate factors, as the 
influence of other AGEs, membrane bound RAGE, pro-
duction and excretion of sRAGE and esRAGE are still 
unknown.
Strengths and limitations
The strengths of this study include the prospective 
design, relatively large cohort of diabetes patients 
and controls and different surrogate markers of ath-
erosclerosis. There are of course also limitations. Non-
invasive measurement of atherosclerosis in children 
and young adults have several inherent shortcomings. 
Only cIMT and CRP are accepted surrogate mark-
ers of atherosclerosis, and best documented in adults 
[45]. Young’s modulus is not the gold standard for 
measuring arterial stiffness, which introduces some 
uncertainty. It is debatable whether AGE’s in the con-
centration found in vivo actually are important ligands 
for RAGE, and there are several other classes of 
ligands for RAGE not considered in this study, includ-
ing the proteins S100/calgranulin and high mobility 
group box 1 (HMGB1) and others [46, 47]. As long as 
the AGE-RAGE-sRAGE and AGE-RAGE-esRAGE axes 
are insufficiently understood, the data must be inter-
preted with caution.
Conclusions
In this study, we have shown a possible protective effect 
of high levels of sRAGE on inflammation, but not on 
arterial stiffness or wall thickness, in this cohort of ado-
lescents and young adults with T1D. We have also shown 
an age-associated decline in values of both sRAGE and 
esRAGE in the teens and early twenties of both T1D 
patients and healthy control subjects.
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